The U.K. government chooses Ilumina (ILMN +1.5%) to sequence 100,000 human genomes in a project focused on cancer, rare and infectious diseases. The pilot phase project, called Genomics England, is expected to be completed by the end of 2017.
One in 17 people are born with or will develop a rare disease in their lifetime. 80% of rare diseases have an identified genetic component.
One of the project's goals is to kickstart the development of a U.K. genomics industry and introduce the technology into its mainstream health system.